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Germline mutations of E-cadherin gene (CDH1)o c c u r
in 30% of families with Hereditary Diffuse Gastric Can-
cer (HDGC); of these, 23% are missense mutations. The
CDH1 missense mutations described to date span the
entire gene and most of them are functionally relevant
and constitute a invaluable model do study E-cadherin
dependent signaling pathways and find new molecular
targets for therapy. Recently, we explored the hypothesis
that mutations affecting different E-cadherin protein
domains have distinct effects on cell motility. To verify
this hypothesis we characterized the effect of eleven
HDGC CDH1 germline missense mutations (T118R,
L214P, G239R, A298T, T340A, P373L, R749W, E757K,
E781D, P799R and V832M) on cell motility. Further, we
studied their effect on the activation of signaling path-
ways known to be relevant for cell motility, such as the
EGFR signaling.
We found that all cell lines expressing extracellular
mutant forms of E-cadherin (T118R, L214P, G239R,
A298T and P373L) displayed higher EGFR activation
than cells expressing wild-type E-cadherin. This pheno-
type is similar to what we observed for cells negative for
E-cadherin, which also displayed increased EGFR phos-
phorylation in comparison to the wild-type expressing
cells. The same pattern was observed for the cells
expressing the intracellular mutations within the juxta-
membrane region, R749W and E757K, which is in
accordance with the motility analysis results. Our results
allowed the identification of the E-cadherin domains
pivotal for cell motility, further demonstrated a geno-
type–phenotype correlation, and defined a subset of
HDGC cases which may benefit from EGFR inhibitors.
The role of E-cadherin in tumor development is well
established, with many human carcinomas exhibiting
E-cadherin loss at the invasive front. In many invasive car-
cinomas, the mechanisms leading to the loss of E-cadherin
remains elusive. We recently hypothesize that trafficking
deregulation has a role in the regulation of E-cadherin mis-
sense mutations. We first analyzed the intracellular traf-
ficking of two HDGC-associated missense mutations,
R749W and E757K, localized in the justamembranar
domain of E-cadherin, know to have higher impact in
E-cadherin trafficking. We found that these mutations
frequently accumulate in the endoplasmic reticulum.
Moreover, treatment of the mutant cells with specific che-
mical chaperones, restored mutant E-cadherin to the cell
membrane and rescued its function. The protein-stabilizing
power of chemical chaperones has been show to be effec-
tive on rescuing different disease-associated mutant pro-
teins, but the mechanism is not understood. In order to
understand and further explore the therapeutic power of
such organic molecules in the context of HDGC, be believe
its crucial to dissect their mode of action in the regulation
of E-cadherin mutants. We are now investigating the
mechanism by which the chemical chaperone DMSO res-
cues mutant E-cadherin expression by analyzing its effect
on different known E-cadherin trafficking regulators.
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